

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A pharmaceutical composition for treatment of a disease, wherein the composition comprises a pharmaceutically acceptable carrier or excipient and at least one modulator that binds to or interferes with the activity of ~~any one of LRP4, LRP8, LRP2 (megalin) and active fragments thereof.~~
LRP4, LRP8, or an active fragment of either.

2. (Currently Amended) The composition of claim 1, wherein the modulator ~~is selected from~~ comprises a small molecule, an RNAi molecule, an anti-sense molecule, ~~and a ribozyme, or an antibody.~~

3. (Currently Amended) The composition of claim ~~[[1]]~~ 2, wherein the modulator ~~[[is]]~~ comprises an antibody.

4. (Currently Amended) The composition of claim 3, wherein the antibody is a ~~human or humanized~~ monoclonal antibody.

Claims 5-8 (Canceled).

9. (Original) The composition of claim 1, wherein the disease is a proliferative disease.

Claim 10 (Canceled).

11. (Currently Amended) The composition of claim 3, wherein the antibody specifically binds to or interferes with the activity of a sequence ~~selected from of any of~~ SEQ ID NOs: ~~10-18 and SEQ ID NOs: 28-126~~ 10-15, 17-18, 28-48, or 112-126.

12. (Currently Amended) The composition of claim 3, wherein the antibody specifically binds to or interferes with the activity of a ligand of ~~any one of LRP4, LRP8, LRP2 (megalin) and active fragments thereof~~ LRP4, a ligand of LRP8, or an active fragment of either.

13. (Currently Amended) A method of treatment of a disease in a subject, comprising the steps of:

- (a) ~~providing the composition of any of claims 1-12 a~~ composition comprising a pharmaceutically acceptable carrier or excipient and at least one modulator that binds to or interferes with the activity of LRP2 (megalin), LRP4, LRP8, or an active fragment of either; and
- (b) administering an amount of the composition to the subject effective to treat the disease.

14. (Currently Amended) The method of claim 13, wherein the disease
[[is]] comprises a proliferative disease.

Claim 15 (Canceled).

16. (Currently Amended) The method of claim 14, wherein the
proliferative disease [[is]] comprises a tumor.

17. (Currently Amended) The method of claim 16, wherein the tumor is
selected from splenic tumor, cervical tumor, leukemia, stomach tumor, liver
tumor, thyroid tumor, skin tumor, breast tumor, lung tumor, kidney tumor, brain
tumor, ~~colon~~ colorectal tumor, ovarian tumor, pancreatic tumor, and lymphoma.

18. (Currently Amended) The method of claim 13, wherein the disease
[[is]] comprises a degenerative disease.

Claim 19 (Canceled).

20. (Currently Amended) The method of claim [[19]] 18, wherein the
degenerative ~~neural~~ disease [[is]] comprises Alzheimer's disease.

Claims 21-45 (Canceled).

46. (Currently Amended) The method of claim ~~[[45]]~~ 13, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of ~~any one of LRP2 (megalin) and active fragments~~ or an active fragment thereof.

47. (Currently Amended) The method of claim 46, wherein the antibody specifically binds to or interferes with ~~at least one~~ a polypeptide ~~selected from~~ of any of SEQ ID NOs: 16 and 49-111.

Claims 48-49 (Canceled).

50. (Original) The method of claim 13, wherein the composition is administered locally or systemically.

51. (Currently Amended) The method of claim ~~[[13]]~~ 50, wherein the composition is administered ~~by intravenous, intraperitoneal, intratumor, intralesion, transdermal, intrathecal, subcutaneous, intranasal administration~~ intravenously, intraperitoneally, intratumorly, intralesionally, transdermally, intrathecally, subcutaneously, intranasally or by inhalation.

52. (Currently Amended) An isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises a sequence of at

least ~~[[6]]~~ six amino acid residues and ~~is selected from wherein the amino acid~~
sequence is any one of SEQ ID NOs: 28-126.

53. (Original) An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a polynucleotide sequence that encodes the polypeptide of claim 52.

54. (Original) A vector comprising the nucleic acid molecule of claim 53 and a regulatory sequence that regulates the expression of the nucleic acid molecule.

55. (Currently Amended) A modified cell comprising the polypeptide of claim 52, the nucleic acid molecule of claim 53, or the vector of claim 54.

56. (Currently Amended) An isolated antibody comprising an antigen-binding domain that binds to or interferes with the activity of ~~[[a]]~~ the polypeptide of claim 52.

Claims 57-70 (Canceled).

71. (Currently Amended) A composition comprising a polypeptide and a modulator, wherein the modulator specifically interferes with the activity or binding of the polypeptide, and wherein the polypeptide ~~is selected from~~

comprises a sequence of any of SEQ ID NOS: 10-18 and 28-126.

72. (Original) The composition of claim 71, wherein the modulator is an antibody.

Claims 73-77 (Canceled).